Oncimmune Holdings plc
Oncimmune Holdings plc, a precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally. The company offers ImmunoINSIGHTS platform, an autoantibody profiling service that provides insights to discover and validate novel biomarkers, validate drug mode of action, improve treatment responses and adverse ev… Read more
Oncimmune Holdings plc (ONC) - Total Assets
Latest total assets as of August 2024: GBX4.90 Million GBX
Based on the latest financial reports, Oncimmune Holdings plc (ONC) holds total assets worth GBX4.90 Million GBX as of August 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Oncimmune Holdings plc - Total Assets Trend (2012–2024)
This chart illustrates how Oncimmune Holdings plc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Oncimmune Holdings plc - Asset Composition Analysis
Current Asset Composition (August 2024)
Oncimmune Holdings plc's total assets of GBX4.90 Million consist of 37.8% current assets and 62.2% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 17.3% |
| Accounts Receivable | GBX311.00K | 6.3% |
| Inventory | GBX238.00K | 4.9% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX391.00K | 8.0% |
| Goodwill | GBX1.58 Million | 32.2% |
Asset Composition Trend (2012–2024)
This chart illustrates how Oncimmune Holdings plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oncimmune Holdings plc's current assets represent 37.8% of total assets in 2024, a decrease from 90.0% in 2012.
- Cash Position: Cash and equivalents constituted 17.3% of total assets in 2024, down from 82.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 39.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 32.2% of total assets.
Oncimmune Holdings plc Competitors by Total Assets
Key competitors of Oncimmune Holdings plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Oncimmune Holdings plc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Oncimmune Holdings plc generates 0.56x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Oncimmune Holdings plc is currently not profitable relative to its asset base.
Oncimmune Holdings plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.69 | 3.91 | 3.91 |
| Quick Ratio | 0.60 | 3.75 | 3.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX-818.00K | GBX 4.14 Million | GBX 6.44 Million |
Oncimmune Holdings plc - Advanced Valuation Insights
This section examines the relationship between Oncimmune Holdings plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 49.27 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -41.9% |
| Total Assets | GBX4.90 Million |
| Market Capitalization | $155.03 USD |
Valuation Analysis
Below Book Valuation: The market values Oncimmune Holdings plc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Oncimmune Holdings plc's assets decreased by 41.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Oncimmune Holdings plc (2012–2024)
The table below shows the annual total assets of Oncimmune Holdings plc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-08-31 | GBX4.90 Million | -41.89% |
| 2023-08-31 | GBX8.44 Million | -51.12% |
| 2022-05-31 | GBX17.26 Million | -28.92% |
| 2021-05-31 | GBX24.28 Million | +135.37% |
| 2020-05-31 | GBX10.31 Million | +9.37% |
| 2019-05-31 | GBX9.43 Million | -34.56% |
| 2018-05-31 | GBX14.41 Million | +124.93% |
| 2017-05-31 | GBX6.41 Million | -42.84% |
| 2016-05-31 | GBX11.21 Million | +474.77% |
| 2015-05-31 | GBX1.95 Million | -21.43% |
| 2014-05-31 | GBX2.48 Million | +23.18% |
| 2013-05-31 | GBX2.02 Million | -21.29% |
| 2012-05-31 | GBX2.56 Million | -- |